A composition comprising mesenchymal precursor or stem cells and their use
OwnerSilviu ITESCU, Paul SIMMONSinventors
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to improved cellular compositions and potency assays for obtaining the same. Such compositions and assays may be suitable for use in treating various inflammatory disorders.
Claims31
A composition comprising a population of culture expanded mesenchymal lineage precursor or stem cells (MLPSC), wherein the population of MLPSCs are culture expanded from a cryopreserved intermediate MLPSC preparation and the culture expanded MLPSCs express a receptor which, upon activation via an inflammatory stimulus, phosphorylates NF-κB, wherein the MLPSCs express a level of the receptor that is sufficient to increase phosphorylation of NF-κB upon activation via the inflammatory stimulus at least 3.5 fold greater than unstimulated MLPSCs.
(canceled)
(canceled)
8-9. (canceled)
A composition comprising a population of culture expanded mesenchymal lineage precursor or stem cells, wherein the composition comprises at least 25×106 cells and, wherein the population of culture expanded cells has been selected for use in treatment of an inflammatory disease by determining expression of least about 200 pg/ml TNF-R1 under culture conditions.
12-13. (canceled)
15-16. (canceled)
A method for determining the therapeutic efficacy of mesenchymal lineage precursor or stem cells comprising:
- (i) obtaining a population comprising mesenchymal lineage precursor or stem cells;
- (ii) culturing the cells in a culture medium;
- and
- (iii) determining the amount of TNF-R1 expressed by the cells into the culture medium under culture conditions, wherein an amount of at least about 100 pg/ml TNF-R1 is indicative of therapeutic efficacy.
18-19. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
35-36. (canceled)
Dependencies are inferred from the claim text.